# US 2024/0190965 A1 · Targeting anti-human pd 1h/vista to treat hematologic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0190965 A1
- Document ID: US20240190965A1
- Status: Published application
- Kind: A1
- Application number: 18/531,168
- Filed: 2023-12-06
- Published: 2024-06-13
- Earliest claimed: 2022-12-09
- Assignees: Vanderbilt University
- Applicants: Vanderbilt University
- Inventors: Tae Kon Kim
- Web page: https://patentgrep.com/patent/US20240190965A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61P 35/02: specific for leukemia
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

As disclosed herein, (1) PD-1H is significantly up-regulated in human AML BM while PD-L1 expression is relatively low; (2) PD-1H is highly expressed on human AML blasts but not on normal CD34+ progenitors; (3) PD-1H expressed on AML blasts contributes to the induction of immune evasion in murine AML models; (4) genetic ablation or antibody blockade of PD-1H reverses immune evasion, leading to anti-leukemia effects in murine AML models and humanized AML models; (5) the effect of anti-PD-1H mAb could be maximized by blocking the PD pathway in murine AML models and humanized AML models. Therefore, disclosed herein is a method for treating a leukemia in a subject that involves co-administering to the subject a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of an antibody that specifically binds PD-1H.

## Claims

### Claim 1

A method for treating a leukemia in a subject, comprising administering to the subject a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of an antibody that specifically binds PD-1H.

### Claim 2 (depends on 2)

The method of claim 2, wherein the leukemia comprises an acute myeloid leukemia (AML).

### Claim 3 (depends on 2)

The method of claim 2, wherein the leukemia comprises a myelodysplastic syndrome (MDS).

### Claim 4 (depends on 2)

The method of claim 2, wherein the leukemia comprises a Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

### Claim 5 (depends on 1)

The method of claim 1, wherein the checkpoint inhibitor comprises an anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, or a combination thereof.